Ovarian Cancers

Ovarian cancer management.- Clinical research in Europe dedicated to ovarian cancers.- Oncogenetics.- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality.- How to evaluate tumor burden before therapeutic decision.- Value of lymphadenectomy.- HYPEC: what is the evidence?.- Onco-fertility applied to ovarian cancers.- First-line systemic therapy (chemo/antiangiogenics).- Elderly.- Treatment at relapse (surgery & systemic treatments).- How to evaluate QoL.- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers.- Particular types of ovarian cancers.- High grade serous carcinoma & BRCA mutation anti-PARP.- Borderline and low grade carcinoma.- Clear Cell carcinoma.- Endometrioid carcinoma.- Mucinous carcinoma.- Carcinosarcoma.- Germ cell tumors.- Sex cord tumors.- Very rare ovarian malignant tumors including small cell carcinoma. Ovarian cancer management.- Clinical research in Europededicated to ovarian cancers.- Oncogenetics.- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality.- How to evaluate tumor burden before therapeutic decision.- Value of lymphadenectomy.- HYPEC: what is the evidence?.- Onco-fertility applied to ovarian cancers.- First-line systemic therapy (chemo/antiangiogenics).- Elderly.- Treatment at relapse (surgery  & systemic  treatments).- How to evaluate QoL.- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers.- Particular types of ovarian cancers.- High  grade  serous  carcinoma & BRCA mutation anti-PARP.- Borderline and low grade carcinoma.- Clear Cell carcinoma.- Endometrioid carcinoma.- Mucinous  carcinoma.- Carcinosarcoma.- Germ cell tumors.- Sex cord tumors.- Very rare ovarian malignant tumors including small cell carcinoma.

Eric Pujade-Lauraine, MD, PhD, is founder of the French GINECO Group, which is devoted to clinical research in gynecologic cancer. He is head of the Women Cancer and Clinical research Department at Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, AP-HP in Paris, France and co-chair of the French gynecologic rare tumor network (TMRG)While receiving his medical degree from the University of Paris VI, Professor Pujade-Lauraine later obtained his PhD degree from the University of Paris VI. He is now professor of Medical Oncology at University Paris Descartes. As well as serving on several advisory boards, Prof Pujade-Lauraine is member of the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the European Society of Gynaecologic Oncology (ESGO). He is also Member of the Executive Board of the European Network of Gynecological Trials (ENGOT) and of the international Gynecologic Cancer Intergroup (GCIG) and is past-chair of this institution. He is co-founder and past Chair of the Gynecologic Cancer Academy (GCA) and of the ENGOT Translational group. He was until 2014 member of the NCI Gynecologic Cancer Steering Committee. Prof Pujade-Lauraine has co-authored more than 160 peer-reviewed articles
Isabelle Ray-Coquard, MD, PhD, is medical oncologist in the Medical Oncology Department and the Institute for Clinical Science at the Centre Leon Berard, the regional Cancer Center in Lyon, France. Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the factors that determine medical practices in oncology. Prof Ray-Coquard also received Master's degrees in medical economy in 1996 and in statistics in1995. Since 2005, Prof Ray-Coquard has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national observatory